BIOMAT Database Logo BIOMAT Database Logo

Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. 2014

Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute (CDRI), Jankipuram Extension, Sector-10, Lucknow 226031, Uttar Pradesh, India.

A series of novel thiazolidin-4-one analogues, characterized by different substitution patterns at positions C-2 and N-3 of the thiazolidin-4-one scaffold for anti-HIV-1 activity has been investigated. Most of the compounds showed anti-HIV-1 activity at micromolar concentrations when tested in TZM-bl cells in vitro. Among the thirty-three compounds tested, compound 16 was the most potent inhibitor of HIV-1 replication against HIV-1IIIB, HIV-1ADA5, HIV-1UG070 and HIV-1VB59 (EC50=0.02, 0.08, 0.08 and 0.08 μM, respectively) with selectivity index (SI=6940, 1735, 1692 and 1692) against tested viral strains, respectively. The results of the present study suggested that the substitution of the nitro group at 6' position of the C-2 phenyl ring and 4,6-dimethylpyridin-2-yl at the N-3 position of thiazolidin-4-one had a major impact on the anti-HIV-1 activity and was found to lower cytotoxicity. The substitution of the heteroaryl ring with bromo group and bicyclic heteroaryl ring at N-3 thiazolidin-4-one was found to lower anti-HIV-1 activity and increase cytotoxicity. The undertaken docking studies thus facilitated the identification of crucial interactions between the HIV-1 RT enzyme and thiazolidin-4-one inhibitors, which can be used to design new potential inhibitors.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Novel Thiazolidin-4-ones as Potential Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase.
October 2019, Molecules (Basel, Switzerland),
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
August 2004, Antiviral research,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors.
September 2016, Chemical biology & drug design,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
December 2012, Journal of medicinal chemistry,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
June 2007, Bioorganic & medicinal chemistry letters,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
August 2006, Bioorganic & medicinal chemistry letters,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
[Design, synthesis and biologic evaluation of diarylbenzimidazole derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors].
November 2009, Yao xue xue bao = Acta pharmaceutica Sinica,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
February 2004, Journal of medicinal chemistry,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Design and synthesis of novel distamycin-modified nucleoside analogues as HIV-1 reverse transcriptase inhibitors.
February 2014, Antiviral research,
Vanangamudi Murugesan, and Nandini Makwana, and Rahul Suryawanshi, and Reshu Saxena, and Rajkamal Tripathi, and Ramesh Paranjape, and Smita Kulkarni, and Seturam B Katti
Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2014, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!